NAF develops and administers our international programs in collaboration with several of the world's foremost international nongovernmental organizations dedicated to reproductive health, and participates in resource and information exchange with these and other highly respected international health care organizations and institutions, in both private and public sectors.
The Future of Abortion;
controversies and care
25 and 26 June 2008
QEII Conference Centre, London, UK
More information: www.futureofabortion.org
The WHO report Safe abortion: technical and policy guidance for health systems is available in in English, Portuguese, Spanish, and Russian. It references NAF's clinical training curriculum and the NAF textbook.
Gynuity works globally with a particular emphasis on resource-poor environments and underserved populations, and has a close working relationship with NAF. One of our collaborative programs includes operations research conducted by Gynuity on the use of mifepristone in South Africa, following NAF's training of providers at the clinical trial sites.
Gynuity has also developed a consensus statement "Instructions for Use of Misoprostol for Women's Health" for the use of misoprostol as a single agent for abortion which may be a cost-effective, evidence-based alternative for mifepristone abortion in areas where mifepristone is unavailable or where the cost is prohibitive.
Please Note: The National Abortion Federation's Clinical Policies Board Committee has reviewed the "Consensus Statement: Instructions for use - Abortion Induction with Misoprostol (Cytotec®) in Pregnancies up to 9 Weeks LMP" produced by Gynuity Health Project and Reproductive Health Technologies Project. The misoprostol-only regimens described in this document are effective for medical abortion up to 9 weeks LMP, though mifepristone/misoprostol regimens are 5-10% more effective and seem to have significantly fewer gastrointestinal side effects.